---

---

publishing date : 2021 - 11 - 01    tags : Fda   

save search

---

Janssen Announces Extension of U.S. FDA BLA PDUFA Date for BCMA CAR-T Ciltacabtagene Autoleucel
Published: 2021-11-01 (Crawled : 21:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -9.41% | O: 0.26% H: 2.0% C: 1.15%
fda pdufa car-t

---

Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
COCP | $1.495 -1.39% 7.6K |

Health Technology

| 71.49% | O: 3.12% H: 3.26% C: 2.72%
covid new drug treatment fda drug

---

Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
THRX | $4.06 0.49% 0 |

| -76.26% | O: 1.05% H: 2.6% C: -0.98%
new drug fda clearance treatment fda application test gastrointestinal drug clearance

---

Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
SIOX | $0.478 -20.5% 40K |

Health Technology

| -75.39% | O: 0.0% H: 6.28% C: 6.28%
fda fda fast track gene therapies fast track gene therapy therapy fast track designation designation

---

COVID-19 Update: FDA Vaccine Approval, Booster Shots, and Trying to Conceive
Published: 2021-11-01 (Crawled : 18:00) - progyny.com
PGNY | $32.68 2.51% 2.45% 1.1M |

Commercial Services

| -46.77% | O: 0.28% H: 2.64% C: 0.65%
covid fda vaccine approval covid-19

---

FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
Published: 2021-11-01 (Crawled : 15:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 11.47% | O: -0.42% H: 0.0% C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 14.02% | O: 1.3% H: 0.0% C: 0.0%
treatment fda myeloid leukemia leukemia fda approval

---

Koning Begins FDA Clinical Screening Trial in Daytona Beach, Florida
Published: 2021-11-01 (Crawled : 15:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320 |

Communications

| Email alert Add to watchlist
fda trial

---

Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
Published: 2021-11-01 (Crawled : 14:00) - biospace.com/
LEXX | $2.27 0.89% 0.88% 62K |

Health Technology

| -64.46% | O: 4.52% H: 0.25% C: -2.16%
fda fda approval

---

COVID-19 Update Webinar: FDA Vaccine Approval, Booster Shots, and Trying to Conceive
Published: 2021-11-01 (Crawled : 13:00) - progyny.com
PGNY | $32.68 2.51% 2.45% 1.1M |

Commercial Services

| -46.77% | O: 0.28% H: 2.64% C: 0.65%
covid fda vaccine approval covid-19

---

Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 48.32% | O: 2.72% H: 0.41% C: -0.38%
CHRS | $2.06 3.0% 2.91% 2.9M |

Health Technology

| -87.63% | O: 1.49% H: 3.83% C: 0.0%
treatment fda fda acceptance

---

Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal CarcinomaFDA has granted the toripalimab BLA Priority Review with a target action date of April 2022
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 48.32% | O: 2.72% H: 0.41% C: -0.38%
CHRS | $2.06 3.0% 2.91% 2.9M |

Health Technology

| -87.63% | O: 1.49% H: 3.83% C: 0.0%
treatment fda fda acceptance granted

---

ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome
Published: 2021-11-01 (Crawled : 12:00) - biospace.com/
ANIP S | $65.49 1.41% 1.39% 210K |

Health Technology

| 69.29% | O: 9.77% H: 41.84% C: 31.63%
multiple sclerosis fda rheumatoid arthritis fda approval sclerosis approval syndros

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---